这是一篇来自已证抗体库的有关
人类 INI1的综述,是根据15篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合INI1 抗体。
INI1 同义词: BAF47; CSS3; INI1; MRD15; PPP1R144; RDT; RTPS1; SNF5; SNF5L1; SWNTS1; Sfh1p; Snr1; hSNFS
圣克鲁斯生物技术
小鼠 单克隆(A-5) | | 圣克鲁斯生物技术 INI1抗体(Santa Cruz, sc-166165)被用于被用于免疫沉淀在小鼠样本上 (图 3e). Nat Commun (2022) ncbi |
小鼠 单克隆(A-5) | - 免疫印迹; 人类; 图 4b
- 免疫印迹基因敲除验证; 小鼠; 图 2f
| 圣克鲁斯生物技术 INI1抗体(Santa Cruz, sc-166165)被用于被用于免疫印迹在人类样本上 (图 4b) 和 被用于免疫印迹基因敲除验证在小鼠样本上 (图 2f). Nat Commun (2021) ncbi |
小鼠 单克隆(F-4) | | 圣克鲁斯生物技术 INI1抗体(Santa Cruz Biotechnology, sc-166164)被用于被用于免疫印迹在人类样本上 (图 3e). Sci Adv (2020) ncbi |
小鼠 单克隆(A-5) | | 圣克鲁斯生物技术 INI1抗体(Santa Cruz Biotechnology, sc-166165)被用于被用于免疫印迹在人类样本上 (图 3b). Nature (2019) ncbi |
艾博抗(上海)贸易有限公司
| | 艾博抗(上海)贸易有限公司 INI1抗体(Abcam, ab 88589)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上 (图 1a). Oncogene (2014) ncbi |
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(D9C2) | - 免疫细胞化学; 人类; 图 2b
- 免疫印迹; 人类; 1:1000; 图 1d
| 赛信通(上海)生物试剂有限公司 INI1抗体(Cell Signaling Technology, D9C2)被用于被用于免疫细胞化学在人类样本上 (图 2b) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 1d). J Virol (2020) ncbi |
domestic rabbit 单克隆(D9C2) | - 染色质免疫沉淀
; 人类; 1:1000; 图 s4d
- 免疫沉淀; 人类; 图 3g
| 赛信通(上海)生物试剂有限公司 INI1抗体(Cell signalling, 8745)被用于被用于染色质免疫沉淀
在人类样本上浓度为1:1000 (图 s4d) 和 被用于免疫沉淀在人类样本上 (图 3g). Nat Commun (2016) ncbi |
domestic rabbit 单克隆(D9C2) | | 赛信通(上海)生物试剂有限公司 INI1抗体(CST, 8745)被用于被用于免疫印迹在人类样本上 (图 1). PLoS ONE (2016) ncbi |
domestic rabbit 单克隆(D9C2) | | 赛信通(上海)生物试剂有限公司 INI1抗体(Cell Signaling Technology, 8745)被用于被用于免疫印迹在人类样本上. Carcinogenesis (2015) ncbi |
domestic rabbit 单克隆(D9C2) | - 免疫沉淀; 人类
- 免疫细胞化学; 人类
- 免疫组化; 人类
- 免疫印迹; 人类
| 赛信通(上海)生物试剂有限公司 INI1抗体(Cell Signaling Technology, 8745)被用于被用于免疫沉淀在人类样本上, 被用于免疫细胞化学在人类样本上, 被用于免疫组化在人类样本上 和 被用于免疫印迹在人类样本上. Oncotarget (2014) ncbi |
碧迪BD
小鼠 单克隆(25/BAF47) | | 碧迪BD INI1抗体(BD Biosciences, 612110)被用于被用于免疫组化在人类样本上浓度为1:200 (图 2). Acta Neuropathol (2021) ncbi |
小鼠 单克隆(25/BAF47) | | 碧迪BD INI1抗体(BD Biosciences, 612110)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:50 (图 1). J Pathol (2016) ncbi |
小鼠 单克隆(25/BAF47) | - 免疫组化-石蜡切片; 人类; 1:100; 表 1
| 碧迪BD INI1抗体(BD Transduction Laboratories, 25/BAF47)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (表 1). Histopathology (2015) ncbi |
小鼠 单克隆(25/BAF47) | | 碧迪BD INI1抗体(BD Transduction Laboratories, 25/BAF47)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. Hum Pathol (2014) ncbi |
小鼠 单克隆(25/BAF47) | | 碧迪BD INI1抗体(BD-Transduction Laboratories, 612110)被用于被用于免疫印迹在人类样本上. Mol Cancer Res (2013) ncbi |
Fulton S, Wenderski W, Lepack A, Eagle A, Fanutza T, Bastle R,
et al. Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome. Nat Commun. 2022;13:6384
pubmed 出版商
Pathak R, Zin F, Thomas C, Bens S, Gayden T, Karamchandani J,
et al. Inhibition of nuclear export restores nuclear localization and residual tumor suppressor function of truncated SMARCB1/INI1 protein in a molecular subset of atypical teratoid/rhabdoid tumors. Acta Neuropathol. 2021;142:361-374
pubmed 出版商
Park Y, Lee J, Yan Z, McKernan K, O Haren T, Wang W,
et al. Interplay of BAF and MLL4 promotes cell type-specific enhancer activation. Nat Commun. 2021;12:1630
pubmed 出版商
Shi H, Tao T, Abraham B, Durbin A, Zimmerman M, Kadoch C,
et al. ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Sci Adv. 2020;6:eaaz3440
pubmed 出版商
Asha K, Balfe N, Sharma Walia N. Concurrent Control of the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: a New Prospect for the Therapeutic Potential of Lipoxin A4. J Virol. 2020;94:
pubmed 出版商
Inoue D, Chew G, Liu B, Michel B, Pangallo J, D Avino A,
et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574:432-436
pubmed 出版商
Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B,
et al. LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells. Nat Commun. 2016;7:13608
pubmed 出版商
Kawano S, Grassian A, Tsuda M, Knutson S, Warholic N, Kuznetsov G,
et al. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. PLoS ONE. 2016;11:e0158888
pubmed 出版商
Karnezis A, Wang Y, Ramos P, Hendricks W, Oliva E, D Angelo E,
et al. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2016;238:389-400
pubmed 出版商
Sakamaki A, Katsuragi Y, Otsuka K, Tomita M, Obata M, Iwasaki T,
et al. Bcl11b SWI/SNF-complex subunit modulates intestinal adenoma and regeneration after γ-irradiation through Wnt/β-catenin pathway. Carcinogenesis. 2015;36:622-31
pubmed 出版商
Rao Q, Xia Q, Wang Z, Li L, Shen Q, Shi S,
et al. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology. 2015;67:121-9
pubmed 出版商
Zhang S, Tang W, Weng S, Liu X, Rao B, Gu J,
et al. Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma. Oncotarget. 2014;5:7183-97
pubmed
Li L, Fan X, Xia Q, Rao Q, Liu B, Yu B,
et al. Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis. Hum Pathol. 2014;45:2247-54
pubmed 出版商
Alfonso Pérez T, Domínguez Sánchez M, Garcia Dominguez M, Reyes J. Cytoplasmic interaction of the tumour suppressor protein hSNF5 with dynamin-2 controls endocytosis. Oncogene. 2014;33:3064-74
pubmed 出版商
Kuwahara Y, Wei D, Durand J, Weissman B. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters. Mol Cancer Res. 2013;11:251-60
pubmed 出版商